Patents Assigned to Amgen Inc.
  • Publication number: 20060223109
    Abstract: The invention provides isolated nucleic acid and amino acid sequences of novel receptors, antibodies to such receptors, methods of detecting such nucleic acids and receptors, and methods of screening for modulators of the receptors.
    Type: Application
    Filed: June 14, 2006
    Publication date: October 5, 2006
    Applicant: Amgen, Inc.
    Inventors: Hui Tian, Jiagang Zhao, Jin-Long Chen, Gene Cutler
  • Patent number: 7115617
    Abstract: The invention encompasses compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions, uses and methods for prophylaxis and treatment of cancer.
    Type: Grant
    Filed: August 21, 2002
    Date of Patent: October 3, 2006
    Assignee: Amgen Inc.
    Inventors: John L. Buchanan, Stuart Chaffee, Jean-Christophe Harmange, Perry M. Novak, Xiaotian Zhu
  • Patent number: 7115607
    Abstract: Selected substituted piperazine compounds of Formula I are effective for prophylaxis and treatment of diseases, such as obesity and the like. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving activation of the melanocortin receptor. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 24, 2002
    Date of Patent: October 3, 2006
    Assignee: Amgen Inc.
    Inventors: Christopher H. Fotsch, Premilla Arasasingham, Yunxin Bo, Ning Chen, Martin H. Goldberg, Nianhe Han, Feng-Yin Hsieh, Michael G. Kelly, Qingyian Liu, Mark H. Norman, Duncan M. Smith, Markian Stec, Nuria Tamayo, Ning Xi, Shimin Xu
  • Publication number: 20060216288
    Abstract: This invention is in the field of pharmaceutical agents and specifically relates to compounds, compositions, uses and methods for treating cancer.
    Type: Application
    Filed: March 21, 2006
    Publication date: September 28, 2006
    Applicant: Amgen Inc
    Inventor: David Chang
  • Patent number: 7112606
    Abstract: Heterocyclic arylsulfonamidobenzylic compounds are provided which are useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases.
    Type: Grant
    Filed: January 29, 2003
    Date of Patent: September 26, 2006
    Assignee: Amgen Inc.
    Inventors: Xian Yun Jiao, Frank Kayser, David J. Kopecky, Sharon McKendry, Derek E. Piper, Andrew K. Shiau
  • Patent number: 7112659
    Abstract: The present invention relates to Fc-OB fusion protein compositions, methods of preparation of such compositions and uses thereof. In particular, the present invention relates to a genetic or chemical fusion protein comprising the Fc immunoglobulin region, derivative or analog fused to the N-terminal portion of the OB protein, derivative or analog.
    Type: Grant
    Filed: February 8, 2005
    Date of Patent: September 26, 2006
    Assignee: Amgen, Inc.
    Inventors: Michael B. Mann, Randy Ira Hecht, Mary Ann Pelleymounter, Christopher Francis Toombs
  • Publication number: 20060211022
    Abstract: The present invention relates to methods of detecting compounds that affect the activity of a therapeutic substance or composition administered to a subject, and to reagents for use in such methods.
    Type: Application
    Filed: February 23, 2006
    Publication date: September 21, 2006
    Applicant: Amgen Inc.
    Inventors: Shuqian Jing, Francesca Civoli, Shalini Gupta, Daniel Halperin, Jason Pennucci, Steven Swanson, Yan Yu
  • Patent number: 7105682
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: January 10, 2002
    Date of Patent: September 12, 2006
    Assignee: Amgen Inc.
    Inventors: Guoqing Chen, Jeffrey Adams, Jean Bemis, Lucian Di Pietro, Celia Dominguez, Daniel Elbaum, Julie Germain, Qi Huang, Joseph L. Kim, Xiaohu Ouyang, Vinod F. Patel, Leon M. Smith, Andrew Tasker, Ning Xi, Shimin Xu, Chester Chenguang Yuan, Michael Croghan, Tae-Seong Kim
  • Patent number: 7105313
    Abstract: The invention provides methods and compositions for screening for pharmacological agents which regulate gene expression in mammals. An exemplary assay involves (a) contacting a mammalian cell comprising a knock-in mutant of a targeted native allele encoding a reporter of gene expression, wherein the expression of the reporter is under the control of the gene expression regulatory sequences of the native allele, with a candidate agent under conditions whereby but for the presence of the agent, the reporter is expressed at a first expression level; and, (b) measuring the expression of the reporter to obtain a second expression level, wherein a difference between the first and second expression levels indicates that the candidate agent modulates gene expression.
    Type: Grant
    Filed: February 13, 2003
    Date of Patent: September 12, 2006
    Assignee: Amgen Inc.
    Inventors: Bei Shan, R. Marc Learned, M. Catherine Amaral, Steven L. McKnight, Fabienne C. de la Brousse, Jin-Long Chen
  • Publication number: 20060199817
    Abstract: The present invention comprises a new class of compounds useful for the prophylaxis and treatment of protein kinase mediated diseases, including inflammation and related conditions. The compounds have a general Formula I wherein A1, A2, B, R1, R2, R3 and R4 are defined herein. The invention also comprises pharmaceutical compositions including one or more compounds of Formula I, uses of such compounds and compositions for treatment of kinase mediated diseases including rheumatoid arthritis, psoriasis and other inflammation disorders, as well as intermediates and processes useful for the preparation of compounds of Formula I.
    Type: Application
    Filed: March 2, 2006
    Publication date: September 7, 2006
    Applicant: Amgen Inc.
    Inventors: Andrew Tasker, Dawei Zhang, Guo-Qiang Cao, Partha Chakrabarti, James Falsey, Bradley Herberich, Randall Hungate, Liping Pettus, Anthony Reed, Robert Rzasa, Kelvin Sham, Maya Thaman, Shimin Xu
  • Publication number: 20060199796
    Abstract: The present invention relates to the compounds of Formula I, their preparation and pharmaceutical compositions comprising them. The compounds and pharmaceutical compositions are useful, for example, for the treatment and prevention of obesity, obesity-related disorders and eating disorders.
    Type: Application
    Filed: August 12, 2005
    Publication date: September 7, 2006
    Applicant: Amgen Inc.
    Inventors: Xi Chen, Xiaoqi Chen, Richard Connors, Kang Dai, Ying Fu, Juan Jaen, Yong-Jae Kim, Leping Li, Mike Lizarzaburu, Jeffrey Mihalic, Stephen Shuttleworth
  • Patent number: 7101681
    Abstract: Methods for identifying modulators of nuclear hormone receptor function comprise the steps of (a) forming a mixture comprising a nuclear hormone receptor, a peptide sensor and a candidate agent, but not a natural coactivator protein of the receptor, wherein the sensor provides direct, in vitro binding to the receptor under assay conditions; (b) measuring an agent-biased binding of the sensor to the receptor; and (c) comparing the agent-biased binding with a corresponding unbiased binding of the sensor to the receptor. In particular embodiments, the sensor comprises an amphipathic alpha helix nuclear hormone interacting domain comprising a recited nuclear hormone transcriptional coactivator motif sequence, the sensor is present at sub-micromolar concentration, the binding reaction occurs in solution, the sensor comprises a fluorescent label and the measuring step comprises detecting fluorescence polarization of the label.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: September 5, 2006
    Assignee: Amgen, Inc.
    Inventors: Kevin Lustig, Patrick Baeuerle, Holger Beckmann, Jin-Long Chen, Bei Shan
  • Patent number: 7101868
    Abstract: Selected compounds are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable derivatives thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: April 12, 2004
    Date of Patent: September 5, 2006
    Assignee: Amgen Inc.
    Inventors: Daniel Elbaum, Benny C. Askew, Jr., Shon Booker, Julie Germain, Gregory J. Habgood, Michael Handley, Tae-Seong Kim, Aiwen Li, Nobuko Nishimura, Vinod F. Patel, Chester Chenguang Yuan, Joseph L. Kim, Guolin Cai, Guoqing Chen, Michael Croghan, Lucian V. Di Pietro, Celia Dominguez, Qi Huang, Leon M. Smith, II, Andrew Tasker, Ning Xi, Shimin Xu
  • Patent number: 7102009
    Abstract: Selected amines are effective for prophylaxis and treatment of diseases, such as angiogenesis mediated diseases. The invention encompasses novel compounds, analogs, prodrugs and pharmaceutically acceptable salts thereof, pharmaceutical compositions and methods for prophylaxis and treatment of diseases and other maladies or conditions involving, cancer and the like. The subject invention also relates to processes for making such compounds as well as to intermediates useful in such processes.
    Type: Grant
    Filed: July 17, 2002
    Date of Patent: September 5, 2006
    Assignee: Amgen Inc.
    Inventors: Vinod F. Patel, Benny Askew, Shon Booker, Guoqing Chen, Lucian V. DiPietro, Julie Germain, Gregory J. Habgood, Qi Huang, Tae-Seong Kim, Aiwen Li, Nobuko Nishimura, Rana Nomak, Babak Riahi, Chester Chenguang Yuan, Daniel Elbaum
  • Publication number: 20060194280
    Abstract: The present invention is generally directed to methods of producing an increase in the enrichment or recovery of preferred forms of IgG proteins. More particularly, the invention relates to subjecting preparations of such recombinant IgG proteins with a reduction/oxidation coupling reagent and optionally a chaotropic agent.
    Type: Application
    Filed: October 21, 2005
    Publication date: August 31, 2006
    Applicant: AMGEN INC.
    Inventors: Thomas Dillon, Douglas Rehder, Pavel Bondarenko, Margaret Ricci, Himanshu Gadgil, Douglas Banks, Joe Zhou, Yuefeng Lu
  • Patent number: 7097834
    Abstract: A novel polypeptide, osteoprotegerin binding protein, involved in osteolcast maturation has been identified based upon its affinity for osteoprotegerin. Nucleic acid sequences encoding the polypeptide, or a fragment, analog or derivative thereof, vectors and host cells for production, methods of preparing osteoprotegerin binding protein, and binding assays are also described. Compositions and methods for the treatment of bone diseases such as osteoporosis, bone loss due to arthritis or metastasis, hypercalcemia, and Paget's disease are also provided.
    Type: Grant
    Filed: December 14, 1998
    Date of Patent: August 29, 2006
    Assignee: Amgen Inc.
    Inventor: William J. Boyle
  • Publication number: 20060191027
    Abstract: The present invention relates to novel Cloaked-2 polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, selective binding agents, and methods for producing Cloaked-2 polypeptides. Also provided for are methods for the treatment, diagnosis, amelioration, or prevention of diseases with Cloaked-2 polypeptides.
    Type: Application
    Filed: January 6, 2006
    Publication date: August 24, 2006
    Applicant: AMGEN INC.
    Inventors: Christopher Paszty, Yongming Gao
  • Publication number: 20060189531
    Abstract: The invention relates to the field of compounds, especially peptides or polypeptides, that have thrombopoietic activity. The peptides and polypeptides of the invention may be used to increase platelets or platelet precursors (e.g., megakaryocytes) in a mammal.
    Type: Application
    Filed: January 19, 2006
    Publication date: August 24, 2006
    Applicant: AMGEN INC.
    Inventors: Chuan-Fa Liu, Ulrich Feige, Janet Cheetham
  • Patent number: 7094566
    Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
    Type: Grant
    Filed: March 16, 2001
    Date of Patent: August 22, 2006
    Assignee: Amgen Inc.,
    Inventors: Eugene Medlock, Richard Yeh, Scott M. Silbiger, Gary S. Elliott, Hung Q. Nguyen, Shuqian Jing
  • Patent number: D530009
    Type: Grant
    Filed: March 15, 2004
    Date of Patent: October 10, 2006
    Assignee: Amgen Inc.
    Inventors: Scott D. Lyman, B. Cameron Smith